p53 Antibody

About the Target

p53 is a tumor suppressor protein encoded by the TP53 gene, acting as a transcription factor that regulates cell cycle arrest, apoptosis, and DNA repair to maintain genomic stability. Structurally, it is a 393-amino acid protein with an N-terminal transactivation domain (TAD), a proline-rich domain (PRD), a central DNA-binding domain (DBD), a tetramerization domain (TET), and a C-terminal regulatory domain (CTD). p53 is primarily expressed in the nucleus, where its levels are tightly controlled by negative regulators like MDM2 and MDMX, which promote its degradation. Depending on the literature source, TP53 may also be discussed as p53.

Reported cellular context includes cytoplasm, cytoskeleton, endoplasmic reticulum, and mitochondrion, which can matter when signal is compared across treatments or changing cell states. Following TP53 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

TP53 is commonly interpreted in the context of cancer, metabolism, and dna damage / repair research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cytoplasm, cytoskeleton, and endoplasmic reticulum, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cytoplasm, cytoskeleton, and endoplasmic reticulum across matched conditions
• changes associated with proliferative state, oncogenic signaling, or treatment response
• responses linked to nutrient status, mitochondrial state, or metabolic rewiring
• stress-induced changes after checkpoint activation or genotoxic challenge

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for TP53. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in TP53 reflect biology rather than handling. When interpreting TP53, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep TP53 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.